Clinical Outcome Assessments (COA) Qualification Program Submissions
Similar Posts
Laboratoire Druide Inc. – 705517 – 05/29/2025
CGMP/Finished Pharmaceuticals/AdulteratedPatient Engagement Collaborative
The Patient Engagement Collaborative (PEC) is an advancement in the FDA’s efforts to strengthen its relationship with patient communities and is being coordinated by the FDA’s Public Engagement Staff.Jose F. Cardona, M.D. Hialeah, FL. EIR issued 11/17/2020
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 11/17/2020
Short Title (70 char) Jose F. Cardona, M.D. Hialeah, FL. EIR issued 11/17/2020
FEI Number 3008031588
Firm Name Jose F. Cardona, M.D.
Record Type EIR
State FL
Establishment Type Clinical InvestigationsBD Provides Update on Voluntary Recall of Certain BD Alaris™ Pump Infusion Sets
FRANKLIN LAKES, N.J. (Sept. 12, 2025) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today expanded their Class I voluntary recall initiated in the United States on July 8, 2025 and expanded on July 17, 2025 to inform customers of worst-case performancSystem Correction: IMPRIS Imaging Inc Issues Correction for IMRIS Neuro III-SV
IMPRIS corrects IMRIS Neuro III-SV models due to the potential of ice blockage in the helium venting pipeSearch List of Extended Use Dates to Assist with Drug Shortages
This is to update and consolidate the extended use date information posted previously to assist with drug shortage (6/15/17 to present).
